AU2438297A - Combinations of angiostatic compounds - Google Patents

Combinations of angiostatic compounds

Info

Publication number
AU2438297A
AU2438297A AU24382/97A AU2438297A AU2438297A AU 2438297 A AU2438297 A AU 2438297A AU 24382/97 A AU24382/97 A AU 24382/97A AU 2438297 A AU2438297 A AU 2438297A AU 2438297 A AU2438297 A AU 2438297A
Authority
AU
Australia
Prior art keywords
combinations
angiostatic compounds
angiostatic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24382/97A
Inventor
Abbot F. Clark
Rupa Doshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU2438297A publication Critical patent/AU2438297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU24382/97A 1996-05-09 1997-04-03 Combinations of angiostatic compounds Abandoned AU2438297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1709696P 1996-05-09 1996-05-09
US60017096 1996-05-09
PCT/US1997/005574 WO1997041844A1 (en) 1996-05-09 1997-04-03 Combinations of angiostatic compounds

Publications (1)

Publication Number Publication Date
AU2438297A true AU2438297A (en) 1997-11-26

Family

ID=21780695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24382/97A Abandoned AU2438297A (en) 1996-05-09 1997-04-03 Combinations of angiostatic compounds

Country Status (2)

Country Link
AU (1) AU2438297A (en)
WO (1) WO1997041844A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026712A2 (en) * 1995-02-28 1996-09-06 Handelman, Joseph, H. Use of angiogenesis suppressors for inhibiting hair growth
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US5981508A (en) * 1997-01-29 1999-11-09 Vanderbilt University Facilitation of repair of neural injury with CM101/GBS toxin
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
TW472051B (en) 1997-05-23 2002-01-11 Chugai Pharmaceutical Co Ltd 2,3-dihydrobenzofuran derivatives
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
WO1999062925A1 (en) * 1998-06-02 1999-12-09 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
US6803448B1 (en) 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US8609614B2 (en) 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19842415A1 (en) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
AU2161300A (en) * 1998-12-17 2000-07-03 Alcon Laboratories, Inc. Stable surgical irrigating solutions
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE19957342A1 (en) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Treatment of interleukin (IL)-12 mediated illnesses comprises simultaneous administration of thalidomide or analogue and antiinflammatory cytokine
WO2001041781A2 (en) * 1999-12-09 2001-06-14 Alcon Universal Ltd. Id protein inhibitors for treating ocular diseases
AU2001228863A1 (en) * 2000-01-31 2001-08-14 Santen Pharmaceutical Co. Ltd. Remedies for ophthalmic diseases
EP1938799B1 (en) * 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
RU2316337C2 (en) 2001-04-24 2008-02-10 Мерк Патент Гмбх Combined therapy by using antiangiogenic agents and tnf-alpha
AU2002358158A1 (en) * 2001-12-19 2003-06-30 D. Collen Research Foundation Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
WO2003074045A1 (en) * 2002-03-05 2003-09-12 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
WO2004037286A2 (en) * 2002-10-23 2004-05-06 F. Hoffmann-La Roche Ag Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1473043A1 (en) * 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
PL2101805T3 (en) 2007-01-18 2013-04-30 Merck Patent Gmbh Integrin ligands for use in treating cancer
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
ITMI20101030A1 (en) * 2010-06-09 2011-12-10 Sergio Capaccioli USE OF ANTISENSE OLIGONUCLEOTIDS FOR THE TREATMENT OF RETINAL DEGENERATIONS AND NEOPLASES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
JPH04506066A (en) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー Suramin-type compounds and anti-angiogenic steroids to inhibit angiogenesis
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
JPH05331070A (en) * 1992-02-07 1993-12-14 Takeda Chem Ind Ltd Antineoplastic agent containing both tnp and interleukin
JPH06157344A (en) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The Preparation for blocking new formation of blood vessel and method of blocking new formation of blood vessel
US5434185A (en) * 1993-05-17 1995-07-18 The University Of Kentucky Research Foundation Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents

Also Published As

Publication number Publication date
WO1997041844A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
AU2438297A (en) Combinations of angiostatic compounds
AU5703398A (en) Novel compounds
AU1271297A (en) Inhibitor of ceramidase
AU4032397A (en) Imidazoquinazoline derivatives
AU3634095A (en) Inhibition of hemoflagellates by camptothecin compounds
AU2186797A (en) Pharmaceutically useful compounds
AU3123697A (en) Angiostatic compounds
AU4925697A (en) Compounds
AUPO264096A0 (en) Value improvement of clays
AU2217797A (en) Synthesis of indolylmaleimides
AU2277597A (en) New inhibitors of sh2-mediated processes
AU4157097A (en) Synthesis of bisindolylmalimides
AU5423298A (en) Novel compounds
AU4276496A (en) 3-Thioheteroaryl cephalosporin compounds, compositions and methods of use
AU3191597A (en) Novel medicinal compositions of hydropyridines
AUPO062696A0 (en) Novel compounds
AU1933297A (en) Manufacture of elongate members
AU5126298A (en) Inhibition of crib-biting
AU3711697A (en) Novel compounds
AU1870295A (en) Novel derivatives of tetramethylcyclopropane
AU2041799A (en) Composition of adsorbent
AU2595297A (en) Use of aminoalkylcarboxylic derivatives
AU3902897A (en) Use of hexahydrolupulones as antibacterial agents
AU5330198A (en) Therapeutic compounds
AU4641497A (en) Novel compounds